Everolimus Survival Benefit Suggested in Updated NET Trial Results

Published: Thursday, Jun 23, 2016
James C. Yao, MD

James C. Yao, MD

Patients with nonfunctioning neuroendocrine tumors (NETs) of lung or gastrointestinal (GI) origin continued to live longer when treated with the mammalian target of rapamycin (mTOR) inhibitor everolimus (Afinitor) than with placebo, ongoing follow-up in a randomized trial has shown.1

As previously reported, the trial met the primary endpoint of progression-free survival (PFS), and a first interim survival analysis showed a trend in favor of the everolimus arm. Follow-up for survival will continue, James C. Yao, MD, a professor at The University of Texas MD Anderson Cancer Center, reported at the 2016 ASCO Annual Meeting.

“The findings from this second interim overall survival analysis continue to suggest a positive trend for survival benefit with everolimus, even though statistical significance was not achieved,” Yao and colleagues concluded in a poster presentation. “The estimated 2-year survival rate was 77% with everolimus versus 62% with placebo.”

A final survival analysis will be performed after approximately 191 deaths have occurred (approximately two-thirds of patients in the trial). The second interim analysis occurred after 101 deaths.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication